MD Anderson Cancer Center and National Institutes of Health

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MD Anderson Cancer Center and National Institutes of Health to Fund Clinical Trial Combining Two Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients

NEW YORK and MELBOURNE, Australia, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast's two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone. 

The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. Combining Mesoblast's proprietary technologies using MPC-based expansion plus ex-vivo fucosylation of cord blood HSCs aims to overcome the two key limitations to using cord blood for rapid, early engraftment and bone marrow reconstitution in adult bone marrow transplant patients. This novel clinical strategy has the potential to significantly increase the number of patients who can receive unrelated donor transplants.   

Previously, Mesoblast conducted a Phase 2 clinical trial which demonstrated that transplantation of HSCs from MPC-expanded cord blood resulted in a reduced engraftment time, from a median of 24 days for placebo-treated cells to a median of 15 days for co-cultured cells. i  Separately, another Phase 2 clinical study showed that transplantation of fucosylated, but non-expanded, cord blood HSCs also resulted in a reduced median engraftment time of 17 days. ii  More recently, preclinical results from a group led by Dr Elizabeth J. Shpall, Director of the Cell Therapy Laboratory and a Professor in the Department of Stem Cell Transplantation at MDACC, where MPC-based expansion and ex vivo-fucosylation technologies were combined, showed a very rapid engraftment time of approximately seven days.   

“Our data suggest that combining Mesoblast’s MPC-based HSC expansion and ex vivo fucosylation technologies may be the optimal clinical strategy for rapid engraftment of cord blood transplants, potentially making cord blood transplantation a real option for many desperate patients who cannot find a suitable alternative,” said Dr Shpall.

The new trial of up to 25 patients, entitled  ‘Cord Blood Ex-vivo MPC Expansion Plus Fucosylation to Enhance Homing and Engraftment ’, is supported by a grant from the NIH National Cancer Institute (NCI Grant R01 CA061508-19) and will be led by Dr Amanda Olson, Assistant Professor, Department of Stem Cell Transplantation and Dr Shpall at MDACC. If the results of the combination study are positive, Mesoblast's proprietary ex vivo-fucosylation technology may be incorporated into the company's Phase 3 program of MPC-expanded HSCs.

About HSC Transplantation Treatment of Patients with Advanced Blood Cancers Many patients with advanced blood cancers, such as acute myeloid leukemia, require a stem cell transplant to repopulate bone marrow HSCs after treatment with high dose chemotherapy. Patients typically undergo transplant with blood stem cells taken from the bone marrow or peripheral blood of a donor with a matched tissue type. However, it may be difficult to find a matched donor, especially for patients who are part of a racial or ethnic minority. While transplants using cord blood-derived stem cells do not require the same degree of donor matching as blood and marrow, this approach has had limited success due to the low yield of stem cells in cord blood and their reduced ability to localize within the recipient’s bone marrow.  

About Ex-Vivo Fucosylation Technology Ex-vivo fucosylation is the addition of the sugar fucose to surface receptors on cells, including HSCs and mesenchymal lineage stem cells. This process modifies receptors on these cells by adding carbohydrate or sugar sequences which allows them to be recognized by and bound to their ligands present on endothelial cells lining blood vessels in inflamed tissues and in human bone marrow.  As a result, such modified cells demonstrate enhanced homing properties to bone marrow or to tissues that are inflamed. Mesoblast has exclusively licensed the ex-vivo fucosylation technology, which was developed at the Harvard Medical School by Dr Robert Sackstein, for use with HSCs and with allogeneic mesenchymal lineage cells.  This cell targeting technology resulted in engraftment of systemically infused human HSCs into mouse bone marrow at a rate ten times that of unmodified human HSCs. iii

About Mesoblast Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions. 

i   N Engl J Med, 2012; 367:2305-15 ii  Blood, 2015; 124(29): 2885-2892 iii  Nature Medicine, 2008; 14: 181-187

Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

For further information, please contact: Julie Meldrum Corporate Communications, Mesoblast T: +61 3 9639 6036 E: julie.meldrum@mesoblast.com Schond Greenway Investor Relations, Mesoblast T: +1 212 880 2060 E: schond.greenway@mesoblast.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 172

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 124

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 51

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 87

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 79

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 34

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 34

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading
Cedar’s Fast 500 Spot Shows Billing Tech’s Momentum

Updated Category News Views 89

A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
YPF’s 2027 Reserves Platform Move Deserves Attention

Updated Category News Views 38

Reservoir software rarely makes anyone pound the table, but this one deserves a hard look. YPF, Argentina’s largest oil and gas company, says it will begin deploying Ikon Science’s MOSAIC reserves planning and management platform in 2027. That is not a new well, a pipeline expansion, or a barrel-count upgrade. It is the machinery behind the machinery: the systems used...

Continue Reading

Top 5 Most Recently Viewed Articles

What Investors Should Know About Annaly Capital Management Now

Updated Category News Views 219

Annaly Capital Management's Upcoming Earnings Report Annaly Capital Management (NYSE:NLY) is scheduled to release its quarterly earnings report soon. Investors are eager to find out how the company is performing and what it might mean for future investments. Analysts predict an earnings per share (EPS) of $0.72, and there is hope that the company will not only meet but...

Continue Reading
Saab Expands Military Partnerships with New Colombian Contract

Updated Category News Views 381

Saab's New Military Contract with Colombia In a significant development for both Saab and the Colombian government, the defense company has successfully secured a contract to supply 17 Gripen E/F fighter aircraft. This milestone order, valued at approximately EUR 3.1 billion, is set to bolster Colombia's air defense capabilities over the coming years. Details of the...

Continue Reading
Senske Family of Companies Strengthens Canadian Services with Acquisitions

Updated Category News Views 187

Senske Family of Companies Strengthens Canadian Services with Acquisitions Senske Family of Companies (SFC) is thrilled to announce its latest expansion by acquiring two notable Nutri-Lawn franchise operations, enhancing its presence and service capabilities. Details of the Acquisitions The newly acquired franchises, Nutri-Lawn Mississauga and Nutri-Lawn Fredericton,...

Continue Reading
Understanding Sunstone Hotel Investors' 2024 Dividend Tax Breakdown

Updated Category News Views 171

Tax Treatment of 2024 Dividends by Sunstone Hotel Investors Sunstone Hotel Investors, Inc. (NYSE: SHO) has provided important insights regarding the tax implications for its 2024 dividend distributions. This announcement is pivotal for shareholders who need to understand the tax treatment applicable to their dividends, particularly as it relates to their income tax...

Continue Reading
Strategizing with BABA: A Comprehensive Butterfly Trade Guide

Updated Category News Views 179

Navigating the Financial Waters with a Double Butterfly Trade In today's complex economic landscape, characterized by mixed signals, investors need to stay agile and informed. While initial public offerings (IPOs) have seen a decline, private equity investment is on the rise. Housing trends are juxtaposed, with new housing starts dropping yet home sales increasing. In the...

Continue Reading